Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Keryx Biopharmaceuticals has reported that following a Drug Safety and Monitoring Committee review of the Sun-Macro Phase IV trial of Sulonex, the company has decided to terminate the study and cease further development of Sulonex.
Subscribe to our email newsletter
The company previously said that the trial had been suspended pending an interim analysis, following which the company would make a decision regarding whether the trial ought to be continued or terminated.
Based on a review of the available proteinuria data, Sulonex did not appear to be different than placebo. The study was not terminated by the Drug Safety and Monitoring Committee for a safety problem or safety signal.